PAMNEU - Memory in Neurology

July 13, 2025 updated by: Tadeáš Mareš, Charles University, Czech Republic

PAMNEU: Easy Detection of Memory Disorders Using Very Short ALBA and PICNIR Tests in Neurological Outpatient Clinics in the Czech Republic

Memory in Neurology project (PAMNEU) aims to map the distribution and severity of cognitive impairment in patients of outpatient neurologic offices across the geographical area of the Czech Republic. 1000 patients in 50 neurologic offices will undergo cognitive tests (ALBA and PICNIR) and psychometric scales (FAQ-CZ and GDS-CZ) to asses their functional state and depressive symptoms.

The trial's primary goal is to assess the distribution of cognitive impairment among diagnostic groups in neurologic care according to the ICD-10. Additionally, the feasibility of ALBA and PICNIR methods to uncover previously undiagnosed cognitive impairments will be evaluated.

Study Overview

Status

Active, not recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Czechia
      • Praha, Czechia, 10000
        • Teaching Hospital Královské Vinohrady

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

The population is intended to be comprised of persons (50yrs+) living in the geographical area of the Czech Republic undergoing treatment at an outpatient neurologic office for a diagnosis defined in ICD-10 (excluding mental retardation). The probability sample will be created by a random selection of persons undergoing their regular outpatient neurologic checkups.

Description

Inclusion Criteria:

  • Dispensarization of at least six months in an outpatient neurologic office with an ICD-10 diagnosis
  • Age>=50
  • Permanent residency in the geographical area of the Czech Republic

Exclusion Criteria:

  • Diagnosis of mental retardation (F70-F79) according to ICD-10
  • Refusal to sign the informed consent and consent with GDPR
  • Uncorrected visual impairment
  • Uncorrected auditory impairment
  • Impairment of hand movement preventing the patient from filling in the questionnaires.
  • Inability to participate in the project

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Observed group
No intervention will be administered on behalf of the project. The participants will be tested using ALBA and PICNIR (non-invasive) cognitive tests, and further FAQ-CZ and GDS-CZ questionnaires will be administered.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline ALBA
Time Frame: Established on Day 0 as a single assessment.
Amnesia Light and Brief Assessment (ALBA) test is an innovative method to assess cognitive functions quickly. The cognitive performance is scaled as an overall score between 0-12 (a lower value denotes a more severe cognitive impairment).
Established on Day 0 as a single assessment.
Baseline PICNIR
Time Frame: Established on Day 0 as a single assessment.
Picture Naming and Immediate Recall test (PICNIR) is an innovative test method to assess cognitive functions quickly. The cognitive performance is scaled as an overall score between 0-20 (a lower value denotes a more severe cognitive impairment).
Established on Day 0 as a single assessment.
Statistical analysis of ALBA results
Time Frame: The final statistical analysis will be performed through study completion, an average of 6 months.
Statistical analysis of ALBA results compared to groups determined by ICD-10 diagnosis and demographical data.
The final statistical analysis will be performed through study completion, an average of 6 months.
Statistical analysis of PICNIR results
Time Frame: The final statistical analysis will be performed through study completion, an average of 6 months.
Statistical analysis of PICNIR results compared to groups determined by ICD-10 diagnosis and demographical data.
The final statistical analysis will be performed through study completion, an average of 6 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline GDS-CZ
Time Frame: Established as a baseline on Day 0.
The Geriatric Depression Scale - Czech version (GDS-CZ) is a standardized questionnaire administered to assess depressive symptoms, particularly in the elderly population. Fifteen items are scaled between 0-1 to reach the overall score between 0-15 (a higher value denotes a higher level of depressive symptoms).
Established as a baseline on Day 0.
Baseline FAQ-CZ
Time Frame: Established as a baseline on Day 0.
Functional Activities Questionnaire - Czech version (FAQ-CZ) is a standardized questionnaire administered to assess a patient´s functional state regarding daily activities. Ten items of daily functioning are scaled between 0-3 (a higher value denotes a higher dependency) to reach the overall score between 0-30 (a higher value denotes a higher dependency). This version of the scale will be used for participants´ self-evaluation.
Established as a baseline on Day 0.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Charles University, Czech Republic

Investigators

  • Principal Investigator: Aleš Bartoš, M.D., Ph.D., Charles University, Czech Republic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2023

Primary Completion (Actual)

May 31, 2024

Study Completion (Estimated)

May 31, 2026

Study Registration Dates

First Submitted

November 19, 2023

First Submitted That Met QC Criteria

November 23, 2023

First Posted (Actual)

December 4, 2023

Study Record Updates

Last Update Posted (Actual)

July 16, 2025

Last Update Submitted That Met QC Criteria

July 13, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PAMNEU

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD is to be shared upon request by a verified researcher. The study director´s discretion is reserved.

IPD Sharing Time Frame

Upon the final publication of the outcomes, indefinitely.

IPD Sharing Access Criteria

Being a verified researcher.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Impairment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe